BioCentury | Dec 17, 2020
Finance

New Italian VC’s first play is Spanish biotech chasing notoriously difficult target

...is expected to start 1Q21.The Milan-based firm debuted early this year with €10 million in backing from LPs Rottapharm...
BioCentury | Feb 12, 2020
Finance

AurorA debuts to back early-stage European biotechs

...head of oncology Europe at Swiss pharma Novartis AG (NYSE:NVS; SIX:NOVN). AurorA Science’s LPs are Rottapharm...
BioCentury | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

...more targeted way, with more trust from authorities,” said Lucio Rovati, CEO and CSO of Rottapharm...
...and Rottapharm Biotech s.r.l. are both testing ADAMTS5 inhibitors. Galapagos’ GLPG1972 is in Phase II; Rottapharm’s...
...that are effective enough given disease heterogeneity. According to Rottapharm CEO and CSO Lucio Rovati, Rottapharm...
BioCentury | Feb 11, 2019
Distillery Therapeutics

Neurology

...for allergy. AskAt and Arrys Therapeutics Inc. have the compound in preclinical testing for cancer. Rottapharm...
BioCentury | Oct 19, 2018
Emerging Company Profile

Altheia: Proliferating PD-L1

...University collaborators: Undisclosed Corporate partners: Undisclosed Number of employees: 7 Funds raised: $11 million Investors: Fidim/Rottapharm...
BioCentury | Sep 28, 2018
Financial News

Altheia lands $11M series A

...its acquisition by Novartis AG (NYSE:NVS; SIX:NOVN) for $3.9 billion last year. Additional investors included Fidim/Rottapharm...
BioCentury | Sep 24, 2018
Financial News

Altheia lands $11M series A

...its acquisition by Novartis AG (NYSE:NVS; SIX:NOVN) for $3.9 billion last year. Additional investors included Fidim/Rottapharm...
BioCentury | Jan 5, 2018
Emerging Company Profile

Against radical pain

...Adynxx Inc.’s brivoligide is a small synthetic dsDNA inhibitor of early growth response 1 (EGR1). Rottapharm...
...pain. That “will differentiate from brivoligide and the others,” he said. In an emailed statement, Rottapharm’s...
...CerSci Therapeutics, Dallas, Texas Galleon Pharmaceuticals Inc., Horsham, Pa. Recro Pharma Inc. (NASDAQ:REPH), Malvern, Pa. Rottapharm...
BioCentury | Jun 27, 2016
Emerging Company Profile

Next-gen NMDA

...Riedel declined to directly compare its technology to similar compounds. Neboglamine ( CR2249 ) from Rottapharm...
...NMDA receptor modulator in development for schizophrenia; the compound has completed four Phase I studies. Rottapharm...
...Aptinyx Inc., Evanston, Ill. Luc Therapeutics Inc., Cambridge, Mass. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Rottapharm...
BioCentury | Nov 24, 2014
Company News

Rottapharm Madaus, Meda deal

...Meda completed its acquisition of Rottapharm for SEK15.3 billion ($2.1 billion) in cash and 30 million...
...of SEK96.70 on Oct. 9, the day before the acquisition closed (see BioCentury, Aug. 4). Rottapharm Madaus Group...
Items per page:
1 - 10 of 34
BioCentury | Dec 17, 2020
Finance

New Italian VC’s first play is Spanish biotech chasing notoriously difficult target

...is expected to start 1Q21.The Milan-based firm debuted early this year with €10 million in backing from LPs Rottapharm...
BioCentury | Feb 12, 2020
Finance

AurorA debuts to back early-stage European biotechs

...head of oncology Europe at Swiss pharma Novartis AG (NYSE:NVS; SIX:NOVN). AurorA Science’s LPs are Rottapharm...
BioCentury | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

...more targeted way, with more trust from authorities,” said Lucio Rovati, CEO and CSO of Rottapharm...
...and Rottapharm Biotech s.r.l. are both testing ADAMTS5 inhibitors. Galapagos’ GLPG1972 is in Phase II; Rottapharm’s...
...that are effective enough given disease heterogeneity. According to Rottapharm CEO and CSO Lucio Rovati, Rottapharm...
BioCentury | Feb 11, 2019
Distillery Therapeutics

Neurology

...for allergy. AskAt and Arrys Therapeutics Inc. have the compound in preclinical testing for cancer. Rottapharm...
BioCentury | Oct 19, 2018
Emerging Company Profile

Altheia: Proliferating PD-L1

...University collaborators: Undisclosed Corporate partners: Undisclosed Number of employees: 7 Funds raised: $11 million Investors: Fidim/Rottapharm...
BioCentury | Sep 28, 2018
Financial News

Altheia lands $11M series A

...its acquisition by Novartis AG (NYSE:NVS; SIX:NOVN) for $3.9 billion last year. Additional investors included Fidim/Rottapharm...
BioCentury | Sep 24, 2018
Financial News

Altheia lands $11M series A

...its acquisition by Novartis AG (NYSE:NVS; SIX:NOVN) for $3.9 billion last year. Additional investors included Fidim/Rottapharm...
BioCentury | Jan 5, 2018
Emerging Company Profile

Against radical pain

...Adynxx Inc.’s brivoligide is a small synthetic dsDNA inhibitor of early growth response 1 (EGR1). Rottapharm...
...pain. That “will differentiate from brivoligide and the others,” he said. In an emailed statement, Rottapharm’s...
...CerSci Therapeutics, Dallas, Texas Galleon Pharmaceuticals Inc., Horsham, Pa. Recro Pharma Inc. (NASDAQ:REPH), Malvern, Pa. Rottapharm...
BioCentury | Jun 27, 2016
Emerging Company Profile

Next-gen NMDA

...Riedel declined to directly compare its technology to similar compounds. Neboglamine ( CR2249 ) from Rottapharm...
...NMDA receptor modulator in development for schizophrenia; the compound has completed four Phase I studies. Rottapharm...
...Aptinyx Inc., Evanston, Ill. Luc Therapeutics Inc., Cambridge, Mass. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Rottapharm...
BioCentury | Nov 24, 2014
Company News

Rottapharm Madaus, Meda deal

...Meda completed its acquisition of Rottapharm for SEK15.3 billion ($2.1 billion) in cash and 30 million...
...of SEK96.70 on Oct. 9, the day before the acquisition closed (see BioCentury, Aug. 4). Rottapharm Madaus Group...
Items per page:
1 - 10 of 34